Research Analysts Offer Predictions for COGT Q1 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Cogent Biosciences in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the technology company will earn ($0.57) per share for the quarter. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Cogent Biosciences’ Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.55) EPS and FY2027 earnings at $0.72 EPS.

Cogent Biosciences (NASDAQ:COGT) last announced its earnings results on Tuesday, November 12th. The technology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). During the same quarter last year, the business posted ($0.64) EPS.

Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. increased their price target on Cogent Biosciences from $19.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Wedbush restated a “neutral” rating and issued a $11.00 price target on shares of Cogent Biosciences in a research note on Monday, January 13th. Needham & Company LLC downgraded Cogent Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, HC Wainwright cut their price target on shares of Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $14.33.

Cogent Biosciences Stock Down 5.1 %

NASDAQ:COGT opened at $9.17 on Friday. Cogent Biosciences has a one year low of $5.37 and a one year high of $12.61. The stock has a 50 day moving average price of $8.44 and a 200 day moving average price of $9.67.

Hedge Funds Weigh In On Cogent Biosciences

A number of hedge funds have recently made changes to their positions in the stock. Barclays PLC lifted its holdings in shares of Cogent Biosciences by 124.8% during the 3rd quarter. Barclays PLC now owns 175,684 shares of the technology company’s stock valued at $1,897,000 after acquiring an additional 97,541 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Cogent Biosciences by 20.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 825,793 shares of the technology company’s stock worth $8,919,000 after acquiring an additional 139,096 shares during the period. The Manufacturers Life Insurance Company grew its position in Cogent Biosciences by 14.5% in the second quarter. The Manufacturers Life Insurance Company now owns 35,752 shares of the technology company’s stock valued at $301,000 after acquiring an additional 4,528 shares in the last quarter. Geode Capital Management LLC increased its stake in Cogent Biosciences by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,280,793 shares of the technology company’s stock worth $24,638,000 after buying an additional 300,062 shares during the period. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in Cogent Biosciences by 34.7% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 171,999 shares of the technology company’s stock valued at $1,858,000 after purchasing an additional 44,287 shares during the last quarter.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.